Song, Jinhua
Wang, Huiling
Ng, Teresa I.
Cui, Aili
Zhu, Shuangli
Huang, Yanzhi
Sun, Liwei
Yang, Zifeng
Yu, Deshan
Yu, Pengbo
Zhang, Hong
Zhang, Yan
Xu, Wenbo
Article History
Received: 9 May 2018
Accepted: 9 November 2018
First Online: 4 December 2018
Competing Interests
: Teresa I. Ng is an employee of AbbVie and may hold stocks or stock options of AbbVie. AbbVie markets palivizumab (Synagis®) in countries outside the US. The other authors declare no competing interest.